Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ieramilimab combinations in advanced TNBC
NCT03499899Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of ieramilimab in triple negative breast cancer (TNBC), sponsored by Novartis. Started Jul 2018; status: completed.
02
Drugs
ieramilimab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03499899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499899.